Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcellx, Inc. - Common Stock
(NQ:
ACLX
)
82.95
-1.60 (-1.89%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arcellx, Inc. - Common Stock
< Previous
1
2
3
4
Next >
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
Today 12:00 EST
Via
Benzinga
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Today 10:50 EST
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via
Investor's Business Daily
14 Analysts Have This To Say About Arcellx
Today 10:04 EST
Via
Benzinga
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Today 7:50 EST
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.
Via
Benzinga
Analyst Expectations For Arcellx's Future
November 08, 2024
Via
Benzinga
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
November 06, 2024
Via
Benzinga
Navigating 7 Analyst Ratings For Arcellx
November 06, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcellx
October 22, 2024
Via
Benzinga
4 Analysts Assess Arcellx: What You Need To Know
October 18, 2024
Via
Benzinga
Assessing Arcellx: Insights From 7 Financial Analysts
August 09, 2024
Via
Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Decoding 8 Analyst Evaluations For Arcellx
July 22, 2024
Via
Benzinga
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
Exposures
Product Safety
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
Via
Investor's Business Daily
The Latest Analyst Ratings For Arcellx
June 18, 2024
Via
Benzinga
Expert Ratings For Arcellx
May 31, 2024
Via
Benzinga
Analyst Expectations For Arcellx's Future
May 14, 2024
Via
Benzinga
Peering Into Arcellx's Recent Short Interest
April 15, 2024
Via
Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
February 29, 2024
Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday.
Via
Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
Via
InvestorPlace
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Via
InvestorPlace
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
January 04, 2024
Via
Benzinga
Decoding Bearish Analog And The Warning Signs You Can't Ignore
February 07, 2024
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
January 16, 2024
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.
Via
InvestorPlace
Exposures
Product Safety
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...
Via
Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via
InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 12, 2023
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.